Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | IARS1 | P41252 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470956 | 0.88 | CA1 (0.47) | TRPV1CA1CA2HPGDKCNA5 | |
| SCHEMBL4188579 | 0.85 | KCNA5 (0.35) | TRPV1CA1CA2HPGDKCNA5 | |
| SCHEMBL4193309 | 0.81 | KCNA5 (0.40) | TRPV1CA1CA2HPGDKCNA5 | |
| SCHEMBL4193311 | 0.81 | KCNA5 (0.40) | TRPV1CA1CA2HPGDKCNA5 | |
| SCHEMBL4490339 | 0.76 | NPC1 (0.46) | CA1CA2HPGDKCNA5L3MBTL1 | |
| SCHEMBL4192882 | 0.75 | CYP2D6 (0.47) | HPGD | |
| SCHEMBL4192886 | 0.75 | CYP2D6 (0.47) | HPGD | |
| SCHEMBL4185887 | 0.72 | ACKR3 (0.42) | KCNA5 | |
| SCHEMBL4185884 | 0.72 | ACKR3 (0.42) | KCNA5 | |
| SCHEMBL4492535 | 0.72 | CA1 (0.47) | TRPV1CA1CA2HPGDKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273905-B2 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | ABBOTT PRODUCTS GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| US-20090203686-A1 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-1871758-A1 | AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS | Solvay Pharmaceuticals GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | SOLVAY PHARMACEUTICALS GMBH | 2006-11-09 | — | — | US | disclosed |
| WO-2006108837-A1 | AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ABCC9 | TRPV1 2919/4885CA1 4713/4885CA2 3423/4885 |
| US-20090203686-A1 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ARG1 | TRPV1 3073/4885CA1 4707/4885CA2 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.